ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI-Litton Negations On Frederick continue; Staffs Not Worried About Possible GAO Probe

July 15, 1977

House Committee Probes NCI $5.2 Billion Sole-Source Contract With SAIC-Frederick.

November 14, 2008

NCAB Gives Final Approval to New Guidelines for P01s

May 29, 1987

The NCI director and acting FDA commissioner called for faster approval of cancer drugs in speech to FDA staff.

October 21, 2005

DCE Advisors approver New Grant Programs In Ovarian Cancer, Biostatistics, Biotech Transfer; Support Services Recompetitions

June 19, 1992

FDA News:: ODAC Commends Ciba For Design Of Trials Legal Issues:

January 10, 1997